CRBN and plasma cell myeloma: From this cohort study, there was a subset of patients (21% relapsed/refractory MM and 25% newly diagnosed MM, respectively) who did not respond to the LD and TD regimen, despite expression of CRBN protein within the myeloma cells, suggesting the possibility of mechanisms of resistance that do not involve CRBN [16].